Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al. · Science Translational Medicine · 2011 · 3.6K citations · Full text

Medicine, Genetics, Oncology +17

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Ryohei Katayama, Alice T. Shaw, Tahsin Khan et al. · Science Translational Medicine · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +17

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

Young Lim Choi, Manabu Soda, Yoshihiro Yamashita et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text

Medicine, Molecular Biology, Oncology +17